Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicine

8 Feb 2025

Abstract excerpt

INTRODUCTION: Despite druggable events to be present in 80 % of neuroblastomapatients within the Princess Máxima Center precision medicine program 'iTHER', clinical uptake of treatment recommendations has been low, and the clinical impact for individual patients remains hard to predict. This stresses the need for a method integrating genomics and transcriptomics with functional approaches into therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Neuroblastoma Research and Treatments
Share to Pluripotent Stem Cells Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39954414
DOI: 10.1016/j.ejca.2025.115275

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicinePMID 39954414Read ↗

Systematic functional drug testing in patient-derived models reveals ex vivo sensitivities associated with clinical outcome in rare solid tumorsSemantic proximity Read ↗

Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity.Semantic proximity Read ↗

Drug response profiling guides precision therapy in relapsed and refractory childhood acute lymphoblastic leukemiaSemantic proximity Read ↗

Integration of Pan-Cancer Cell Line and Single-Cell Transcriptomic Profiles Enables Inference of Therapeutic Vulnerabilities in Heterogeneous TumorsSemantic proximity Read ↗

A Functional Precision Medicine Pipeline Combines Comparative Transcriptomics and Tumor Organoid Modeling to Identify Bespoke Treatment Strategies for GlioblastomaSemantic proximity Read ↗

The landscape of drug sensitivity and resistance in sarcomaSemantic proximity Read ↗

Pan-Cancer PDOs Preserve Tumor Heterogeneity and Uncover Therapeutic VulnerabilitiesSemantic proximity Read ↗

BOGO: A Proteome-Wide Gene Overexpression Platform for Discovering Rational Cancer Combination TherapiesSemantic proximity Read ↗

Single-cell RNA sequencing explored potential therapeutic targets by revealing the tumor microenvironment of neuroblastoma and its expression in cell deathSemantic proximity Read ↗

Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.Semantic proximity Read ↗

Inferring therapeutic vulnerability within tumors through integration of pan-cancer cell line and single-cell transcriptomic profilesSemantic proximity Read ↗

Melanoma cell states define therapeutic vulnerabilities in a multimodal single-cell atlasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.